Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD
IntroductionEarlier studies exploring the value of executive functioning (EF) indices for assessing treatment effectiveness and predicting treatment response in attention-deficit/hyperactivity disorder (ADHD) mainly focused on pharmacological treatment options and revealed rather heterogeneous resul...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1331004/full |
| _version_ | 1797351284261519360 |
|---|---|
| author | Anna Kaiser Pascal M. Aggensteiner Hilario Blasco Fontecilla Tomas Ros Eric Acquaviva Yohan Attal Tobias Banaschewski Sarah Baumeister Elisa Bousquet Aurore Bussalb Marie Delhaye Richard Delorme Renate Drechsler Allison Goujon Alexander Häge Louis Mayaud Konstantin Mechler Caroline Menache Olivier Revol Friederike Tagwerker Susanne Walitza Anna Maria Werling Stéphanie Bioulac Stéphanie Bioulac Diane Purper-Ouakil Diane Purper-Ouakil Diane Purper-Ouakil Daniel Brandeis Daniel Brandeis Daniel Brandeis Daniel Brandeis |
| author_facet | Anna Kaiser Pascal M. Aggensteiner Hilario Blasco Fontecilla Tomas Ros Eric Acquaviva Yohan Attal Tobias Banaschewski Sarah Baumeister Elisa Bousquet Aurore Bussalb Marie Delhaye Richard Delorme Renate Drechsler Allison Goujon Alexander Häge Louis Mayaud Konstantin Mechler Caroline Menache Olivier Revol Friederike Tagwerker Susanne Walitza Anna Maria Werling Stéphanie Bioulac Stéphanie Bioulac Diane Purper-Ouakil Diane Purper-Ouakil Diane Purper-Ouakil Daniel Brandeis Daniel Brandeis Daniel Brandeis Daniel Brandeis |
| author_sort | Anna Kaiser |
| collection | DOAJ |
| description | IntroductionEarlier studies exploring the value of executive functioning (EF) indices for assessing treatment effectiveness and predicting treatment response in attention-deficit/hyperactivity disorder (ADHD) mainly focused on pharmacological treatment options and revealed rather heterogeneous results. Envisioning the long-term goal of personalized treatment selection and intervention planning, this study comparing methylphenidate treatment (MPH) and a home-based neurofeedback intervention (NF@Home) aimed to expand previous findings by assessing objective as well as subjectively reported EF indices and by analyzing their value as treatment and predictive markers.MethodsChildren and adolescents (n = 146 in the per protocol sample) aged 7–13 years with a formal diagnosis of an inattentive or combined presentation of ADHD were examined. We explored the EF performance profile using the Conners Continuous Performance Task (CPT) and the BRIEF self-report questionnaire within our prospective, multicenter, randomized, reference drug-controlled NEWROFEED study with sites in five European countries (France, Spain, Switzerland, Germany, and Belgium). As primary outcome for treatment response, the clinician-rated ADHD Rating Scale-IV was used. Patients participating in this non-inferiority trial were randomized to either NF@home (34–40 sessions of TBR or SMR NF depending on the pre-assessed individual alpha peak frequency) or MPH treatment (ratio: 3:2). Within a mixed-effects model framework, analyses of change were calculated to explore the predictive value of neurocognitive indices for ADHD symptom-related treatment response.ResultsFor a variety of neurocognitive indices, we found a significant pre-post change during treatment, mainly in the MPH group. However, the results of the current study reveal a rather limited prognostic value of neurocognitive indices for treatment response to either NF@Home or MPH treatment. Some significant effects emerged for parent-ratings only.DiscussionCurrent findings indicate a potential value of self-report (BRIEF global score) and some objectively measured neurocognitive indices (CPT commission errors and hit reaction time variability) as treatment markers (of change) for MPH. However, we found a rather limited prognostic value with regard to predicting treatment response not (yet) allowing recommendation for clinical use. Baseline symptom severity was revealed as the most relevant predictor, replicating robust findings from previous studies. |
| first_indexed | 2024-03-08T12:58:05Z |
| format | Article |
| id | doaj.art-55fca54dcf864bc9919483401e4d6b43 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-03-08T12:58:05Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-55fca54dcf864bc9919483401e4d6b432024-01-19T14:23:53ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402024-01-011410.3389/fpsyt.2023.13310041331004Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHDAnna Kaiser0Pascal M. Aggensteiner1Hilario Blasco Fontecilla2Tomas Ros3Eric Acquaviva4Yohan Attal5Tobias Banaschewski6Sarah Baumeister7Elisa Bousquet8Aurore Bussalb9Marie Delhaye10Richard Delorme11Renate Drechsler12Allison Goujon13Alexander Häge14Louis Mayaud15Konstantin Mechler16Caroline Menache17Olivier Revol18Friederike Tagwerker19Susanne Walitza20Anna Maria Werling21Stéphanie Bioulac22Stéphanie Bioulac23Diane Purper-Ouakil24Diane Purper-Ouakil25Diane Purper-Ouakil26Daniel Brandeis27Daniel Brandeis28Daniel Brandeis29Daniel Brandeis30Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, GermanyDepartment of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, GermanyUNIR Health Sciences School and Medical Center and UNIR-itei, CIBERSAM, Madrid, SpainDepartment of Neuroscience, Campus Biotech CISA-Université de Genève, Genève, SwitzerlandChild and Adolescent Psychiatry Department and Child Brain Institute, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris and Universite Paris Cite, Paris, FrancemyBrain Technologies, Paris, FranceDepartment of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, GermanyDepartment of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, GermanyUnit of Child and Adolescent Psychiatry (MPEA1), CHU Montpellier-Saint Eloi Hospital, University of Montpellier, Montpellier, FranceMensia Technologies, Paris, FranceChild and Adolescent Psychiatry, Erasme Academic Hospital, Université Libre de Bruxelles, Bruxelles, BelgiumChild and Adolescent Psychiatry Department and Child Brain Institute, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris and Universite Paris Cite, Paris, FranceDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, SwitzerlandUnit of Child and Adolescent Psychiatry (MPEA1), CHU Montpellier-Saint Eloi Hospital, University of Montpellier, Montpellier, FranceDepartment of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, GermanyMensia Technologies, Paris, FranceDepartment of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany0Clinique des Grangettes, Chêne-Bougeries, Geneva, Switzerland1Unit of Child and Adolescent Psychiatry, Hospices civils de Lyon, Hôpital Femme Mère Enfant, Bron Cedex, FranceDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, SwitzerlandDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, SwitzerlandDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland2SANPSY, USR 3413, CNRS, Bordeaux, France3Clinique du Sommeil, CHU Pellegrin, Bordeaux Cedex, FranceUnit of Child and Adolescent Psychiatry (MPEA1), CHU Montpellier-Saint Eloi Hospital, University of Montpellier, Montpellier, France4Development and Trajectories, INSERM CESP U 1018 Psychiatry, Montpellier, France5CESP, INSERM U 1018, Paul Brousse Hospital, Villejuif, FranceDepartment of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, GermanyDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland6Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland7Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, SwitzerlandIntroductionEarlier studies exploring the value of executive functioning (EF) indices for assessing treatment effectiveness and predicting treatment response in attention-deficit/hyperactivity disorder (ADHD) mainly focused on pharmacological treatment options and revealed rather heterogeneous results. Envisioning the long-term goal of personalized treatment selection and intervention planning, this study comparing methylphenidate treatment (MPH) and a home-based neurofeedback intervention (NF@Home) aimed to expand previous findings by assessing objective as well as subjectively reported EF indices and by analyzing their value as treatment and predictive markers.MethodsChildren and adolescents (n = 146 in the per protocol sample) aged 7–13 years with a formal diagnosis of an inattentive or combined presentation of ADHD were examined. We explored the EF performance profile using the Conners Continuous Performance Task (CPT) and the BRIEF self-report questionnaire within our prospective, multicenter, randomized, reference drug-controlled NEWROFEED study with sites in five European countries (France, Spain, Switzerland, Germany, and Belgium). As primary outcome for treatment response, the clinician-rated ADHD Rating Scale-IV was used. Patients participating in this non-inferiority trial were randomized to either NF@home (34–40 sessions of TBR or SMR NF depending on the pre-assessed individual alpha peak frequency) or MPH treatment (ratio: 3:2). Within a mixed-effects model framework, analyses of change were calculated to explore the predictive value of neurocognitive indices for ADHD symptom-related treatment response.ResultsFor a variety of neurocognitive indices, we found a significant pre-post change during treatment, mainly in the MPH group. However, the results of the current study reveal a rather limited prognostic value of neurocognitive indices for treatment response to either NF@Home or MPH treatment. Some significant effects emerged for parent-ratings only.DiscussionCurrent findings indicate a potential value of self-report (BRIEF global score) and some objectively measured neurocognitive indices (CPT commission errors and hit reaction time variability) as treatment markers (of change) for MPH. However, we found a rather limited prognostic value with regard to predicting treatment response not (yet) allowing recommendation for clinical use. Baseline symptom severity was revealed as the most relevant predictor, replicating robust findings from previous studies.https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1331004/fullneurocognitive functioningexecutive functionsADHDpredictive markertreatment markermethylphenidate |
| spellingShingle | Anna Kaiser Pascal M. Aggensteiner Hilario Blasco Fontecilla Tomas Ros Eric Acquaviva Yohan Attal Tobias Banaschewski Sarah Baumeister Elisa Bousquet Aurore Bussalb Marie Delhaye Richard Delorme Renate Drechsler Allison Goujon Alexander Häge Louis Mayaud Konstantin Mechler Caroline Menache Olivier Revol Friederike Tagwerker Susanne Walitza Anna Maria Werling Stéphanie Bioulac Stéphanie Bioulac Diane Purper-Ouakil Diane Purper-Ouakil Diane Purper-Ouakil Daniel Brandeis Daniel Brandeis Daniel Brandeis Daniel Brandeis Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD Frontiers in Psychiatry neurocognitive functioning executive functions ADHD predictive marker treatment marker methylphenidate |
| title | Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD |
| title_full | Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD |
| title_fullStr | Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD |
| title_full_unstemmed | Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD |
| title_short | Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD |
| title_sort | limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback home in children and adolescents with adhd |
| topic | neurocognitive functioning executive functions ADHD predictive marker treatment marker methylphenidate |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1331004/full |
| work_keys_str_mv | AT annakaiser limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT pascalmaggensteiner limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT hilarioblascofontecilla limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT tomasros limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT ericacquaviva limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT yohanattal limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT tobiasbanaschewski limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT sarahbaumeister limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT elisabousquet limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT aurorebussalb limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT mariedelhaye limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT richarddelorme limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT renatedrechsler limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT allisongoujon limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT alexanderhage limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT louismayaud limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT konstantinmechler limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT carolinemenache limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT olivierrevol limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT friederiketagwerker limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT susannewalitza limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT annamariawerling limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT stephaniebioulac limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT stephaniebioulac limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT dianepurperouakil limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT dianepurperouakil limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT dianepurperouakil limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT danielbrandeis limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT danielbrandeis limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT danielbrandeis limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd AT danielbrandeis limitedusefulnessofneurocognitivefunctioningindicesaspredictivemarkersfortreatmentresponsetomethylphenidateorneurofeedbackhomeinchildrenandadolescentswithadhd |